Clinical Trial Update: Slow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSD [Phase 3]

View source ↗

Summary

Phase 3 trial update examining slow vs rapid glucocorticoid tapering in NMOSD patients treated with inebilizumab. The study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica
• Neuromyelitis Optica Spectrum Disorders

Drugs mentioned

• Uplizna (inebilizumab)

Snippet

Sponsor: Tianjin Medical University General Hospital | Conditions: Neuromyelitis Optica (NMO), Neuromyelitis Optica Spectrum Disorders (NMOSD) | Phase 3 | Status: NOT_YET_RECRUITING